We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scapa Group Plc | LSE:SCPA | London | Ordinary Share | GB0007281198 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 214.50 | 214.50 | 215.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSCPA
RNS Number : 4733D
Scapa Group PLC
10 October 2018
10 October 2018
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc ("Scapa" or "the Group")
Period end update
Scapa Group plc (AIM: SCPA) is today providing a period end update for the six months ended 30 September 2018.
Group trading profits* and margins are ahead of last year. Primarily due to the adverse currency movement against the equivalent period last year, revenue is down 3.4%.
Healthcare revenue grew 0.2% (3.4% on a constant currency basis). We anticipate the tech transfers and new programs will, as previously announced, start to benefit revenues during the second half of the year.
Industrial profit and margin improved on lower revenue, and we continue to make good progress toward the medium term margin target of 15%. The integration of Markel Industries is nearly complete and we expect the synergy benefit to come through during the second half of the year. We also announced the closure of our Liverpool facility in New York, USA.
Our cash generation remains strong and the Group ended the first six months with a net debt of GBP5.2m.
We remain confident of strong progress for the year and we anticipate the profit for the year will be in line with expectations, excluding the impact of the recently announced Gargrave healthcare transaction. Further details and the impact of this transaction will be included in the half year results which we expect to announce on 20 November 2018.
*Before exceptional items, amortisation of intangible assets and legacy pension costs and finance charges
Enquiries:
Scapa Group plc Heejae Chae - Chief Executive Oskar Zahn - Chief Financial Officer 0161 301 7430 Numis Securities Limited (Nominated Adviser) Mark Lander / Richard Thomas 020 7260 1000 Berenberg (Joint Broker) Chris Bowman 020 3207 7800 Weber Shandwick Nick Oborne 020 7067 0721
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TSTFKCDNPBDDCKK
(END) Dow Jones Newswires
October 10, 2018 02:00 ET (06:00 GMT)
1 Year Scapa Chart |
1 Month Scapa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions